Clinical trial

KAP for Depression in Abstinent Opioid Users

Medical University of South CarolinaTerminatedPhase 2Started Jan 13, 20225 enrolledUnited StatesNCT05193318

Abstract

The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepressionAddiction

Keywords

Opioid Use Disorder, Severe, in Sustained RemissionOpioid Use Disorder, Severe, in Early RemissionMajor Depressive Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.

Chiappini S, d'Andrea G, De Filippis S +10

Europe PMC2023

ArticleMDMA

Prevalence and Psychiatric Correlates of Illicit Substance Use in UK Undergraduate Students.

Foster H, Stevenson J, Akram U

Europe PMC2023